Role of cytomegalovirus infection in allograft rejection: A review of possible mechanisms

Transplant Immunology

Volumn 7, Issue 2, 1999, Pages 75-82

  Borchers, Andrea T ^a   Perez, Richard ^a   Kaysen, George ^a   Ansari, Aftab A ^b   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; ENVELOPE PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN RECOGNITION; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BIOPSY; CELL PROLIFERATION; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GRAFT REJECTION; HEART GRAFT; HUMAN; INFLAMMATION; LEUKOCYTE; LYMPHOCYTE; NONHUMAN; PARENCHYMA; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0032821008     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(99)80023-9     Document Type: Review

References (87)

1. Koffron AJ, Hummel M, Patterson BK, et al. Cellular localization of latent murine cytomegalovirus. J Virology. 72:1998;95-103.
2. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet. 2:1983;644-647.
3. Yamashiroya HM, Ghosh L, Yang R, Robertson AL Jr. Herspesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol. 130:1988;71-79.
4. Hendrix MG, Dormans PH, Kitslaar P, Bosman F, Bruggeman CA. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients. Am J Pathol. 134:1989;1151-1157.
5. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol. 136:1990;23-28.
6. Hendrix RM, Wagenaar M, Slobbe RL, Bruggeman CA. Widespread presence of cytomegalovirus DNA in tissues of healthy trauma victims. J Clin Pathol. 50:1997;59-63.
7. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J. 14:1993;30-38.
8. von Willebrand E, Pettersson E, Ahonen J, Häyry P. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation. 42:1986;364-367.
9. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 261:1989;3561-3566.
10. Loebe M, Schuler S, Zais O, Warnecke H, Fleck E, Hetzer R. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant. 9:1990;707-711.
11. Everett JP, Hershberger RE, Norman DJ, et al. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant. 11:1992;S133-S137.
12. Bando K, Paradis IL, Komatsu K, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg. 109:1995;49-59.
13. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske B. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int. 49:1996;518-524.
14. Fietze E, Prösch S, Reinke P, et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation. 58:1994;675-680.
15. Reinke P, Fietze E, Ode-Hakim, et al. Late acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet. 344:1994;1737-1738.
16. Martelius T, Krongerus L, Höckerstedt K, Bruggeman C, Lautenschlager I. Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology. 27:1998;996-1002.
17. Stovin PGI, Wreghitt TG, English TAH, Wallwork J. Lack of association between cytomegalovirus infection of heart and rejection-like inflammation. J Clin Pathol. 4:1989;81-83.
18. Koskinen PK, Mieminen MS, Krogerus LA, et al. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant. 12:1993;724-729.
19. Mangiavacchi M, Frigerio M, Gronda E, et al. Acute rejection and cytomegalovirus infection: correlation with cardiac allograft vasculopathy. Transplant Proc. 27:1995;1960-1962.
20. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart. 14:1993;12-16.
21. Koskinen PK, Krogerus LA, Nieminen MS, Mattila SP, Häyry PJ, Lautenschlager IT. Quantitation and cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts. J Heart Lung Transplant. 12:1993;343-354.
22. Bruggeman CA, Li F, Stals FS. Pathogenicity: animal models. Scand J Infect Dis. 99:1995;43-50.
23. Lautenschlager I, Soots A, Krogerus L, et al. Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat. Transplantation. 64:1997;391-398.
24. Yilmaz S, Koskinen PK, Kallio E, Bruggeman CA, Häyry PJ, Lemström KB. Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with interacellular adhesion molecule-1 expression. Kidney Int. 50:1996;526-537.
25. Steinhoff G, You X-M, Steinmüller C, et al. Enhancement of cytomegalovirus infection and acute rejection after allogenic lung transplantation in the rat. I. Viral induction expression of endothelial cell adhesion molecules. Transplantation. 61:1996;1250-1260.
26. Lemström K, Sihvola R, Bruggeman C, Häyry P, Koskinen P. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation. 95:1997;2614-2616.
27. O'Grady JG, Alexander GJM, Sutherlkand S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bileduct syndrome after liver transplantation. Lancet. 2:1988;302-305.
28. Fernando S, Booth J, Boriskin Y, et al. Association of cytomegalovirus infection with post-transplantation cardiac rejection as studied using the polymerase chain reaction. J Med Virol. 42:1994;396-404.
29. Briscoe DM, Ganz P, Alexander SI, et al. The problem of chronic rejection: influence of leukocyte-endothelial interactions. Kidney Int. 51:1997;S22-S27.
30. Steinhoff G, Behrend M, Haverich A. Signs of endothelial inflammation in human heart allografts. Eur Heart J. 12:1991;141-143.
31. Taylor PM, Rose ML, Yacoub MH, Pigott R. Induction of vascular adhesion molecules during rejection of human cardiac allografts. Transplantation. 54:1992;451-457.
32. Koskinen PK. The association of the induction of vascular cell adhesion molecule-1 with cytomegalovirus antigenemia in human heart allografts. Transplantation. 56:1993;1103-1108.
33. Carlos T, Gordon D, Fishbein D, et al. Vascular cell adhesion molecule-1 is induced on endothelium during acute rejection in human cardiac allografts. J Heart Lung Transplant. 11:1992;1103-1108.
34. Lautenschlager IT, Hockerstedt KA. ICAM-1 induction on hepatocytes as a marker for immune activation of acute liver allograft rejection. Transplantation. 56:1993;1495-1499.
35. Bacchi CE, Marsh CL, Perkins JD, et al. Expression of vascular cell adhesion molecule (VCAM-1) in liver and pancreas allograft rejection. Am J Pathol. 142:1993;579-591.
36. Dahmen U, Bergese SD, Qian S, et al. Patterns of inflammatory vascular endothelial changes in murine liver grafts. Transplantation. 60:1995;577-584.
37. Nakakura EK, McCabe SM, Zheng B, et al. Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of nonprimary vascularized heart allograft survival in mice without T cell depletion. Transplantation. 55:1993;412-417.
38. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 255:1992;1125-1127.
39. Orosz CG, Huang EH, Bergese SD, et al. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling. J Heart Lung Transplant. 16:1997;889-904.
40. Bergese SD, Huang EH, Pelletier RP, Widmer MB, Ferguson RM, Orosz CG. Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-a or IL-4 and is not required for allograft rejection. Am J Pathol. 147:1995;155-175.
41. Rothlein R, Jaeger JR. Treatment of inflammatory diseases with a monoclonal antibody to intercellular adhesion molecule 1. Ciba Foundation Symposium. 189:1995;200-208.
42. Le Mauff B, Hourmant M, Le Meuer Y, et al. Anti-LFA-1 adhesion molecule monoclonal antibody in prophylaxis of human kidney allograft rejection. Transplant Proc. 27:1995;865-866.
43. Sedmak DD, Knight DA, Vook NC, Waldman JW. Divergent patterns of ELAM-1, ICAM-1, and VCAM-1 expression on cytomegalovirus-infected endothelial cells. Transplantation. 58:1994;1379-1385.
44. Grundy JE, Downes KL. Up-regulation of LFA-3 and ICAM-1 on the surface of fibroblasts infected with cytomegalovirus. Immunology. 78:1993;405-412.
45. Craigen JL, Grundy JE. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation. 62:1996;1102-1108.
46. Steinhoff G, Wonigeit K, Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Trasplantation. 45:1988;394-401.
47. Ustinov JA, Loginov RJ, Bruggeman CA, van der Meide P.H, Häyry PJ, Lautenschlager IT. Cytomegalovirus induces class II expression in rat heart endothelial cells. J Heart Lung Transplant. 12:1993;644-651.
48. van Dorp WT, van Wieringen PAM, Marselis-Jonges E, et al. Cytomegalovirus directly enhances MHC class I and intercellular adhesion molecule-1 expression on cultured proximal tubular epithelial cells. Transplantation. 55:1993;1367-1371.
49. Sedmak DD, Roberts WH, Stephens RE, et al. Inability of cytomegalovirus infection of cultured endothelial cells to induce HLA class II antigen expression. Transplantation. 49:1990;458-462.
50. Hosenpud JD, Chou S, Wagner CR. Cytomegalovirus-induced regulation of major histocompatibility complex class I antigen expression in human aortic smooth muscle cells. Transplantation. 52:1991;896-903.
51. Ibrahim L, Doinguez M, Yacoub M. Primary human adult lung epithelial cells in vitro: response to interferon-γ and cytomegalovirus. Immunology. 79:1993;119-124.
52. Sedmak DD, Chaiwiriyakul S, Knight DA, Waldman WJ. The role of interferon β in human cytomegalovirus-mediated inhibition of HLA DR induction on endothelial cells. Arch Virol. 140:1995;111-126.
53. + T cells. Transplantation. 56:1993;1504-1512.
54. van Dorp WT, Jonges E, Bruggeman CA, Daha MR, van Es LA, van der Woude FJ. Direct induction of MHC class I, but not class II, expression on endothelial cells by cytomegalovirus infection. Transplantation. 48:1989;469-472.
55. Sedmak DD, Guglielmo AM, Knight DA, Birmingham DJ, Huang EH, Waldman WJ. Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. Am J Pathol. 144:1994;683-692.
56. Yamashita YSK, Mizuno S, Yamaguchi H, Nishiyama Y. Down-regulation of the surface expression of class I MHC antigens by human cytomegalovirus. Virology. 193:1993;727-736.
57. Browne H, Smith G, Beck S, Minson T. A complex between the MHC class I homologue encoded by human cytomegalovirus and β, microglobulin. Nature. 347:1990;770-772.
58. Ustinov J, Bruggeman C, Häyry P, Lautenschlager I. Cytomegalovirus-induced Class II expression in rat kidney. Transplant Proc. 26:1994;1729.
59. You X-M, Steinmüller C, Wagner TOF, Bruggeman CA, Haverich A, Steinhoff G. Enhancement of cytomegalovirus infection and acute rejection after allogeneic lung transplantation in the rat: virus-induced expression of major histocompatibility complex class II antigens. J Heart Lung Transplant. 15:1996;1108-1119.
60. Arbustini E, Morbinie P, Grasso M, et al. Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in transplanted lung. Transplantation. 61:1996;418-427.
61. Speir E, Modali R, Huang E-S, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 265:1994;391-394.
62. Alcami J, Barzu T, Michelson S. Induction of an endothelial cell growth factor by human cytomegalovirus infection of fibroblasts. J Gen Vir. 72:1991;2765-2770.
63. 1 in rat aortic allografts. Possible mechanism for cytomegalovirus-enhanced graft arteriosclerosis. Arterioscler Thromb. 14:1994;2043-2052.
64. Lemström KB, Brunning JH, Bruggeman CA, et al. Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation. 90:1994;1969-1978.
65. Chou S, Dennison KM. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis. 163:1991;1229-1234.
66. Rasmussen L, Hong C, Zipeto D, et al. Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. J Infect Dis. 175:1997;179-184.
67. Peek R, Verbraak F, Bruinenberg M, van der Lelij A, van den Horn G, Kijlstra A. Cytomegalovirus glycoprotein B genotyping in ocular fluids and blood of AIDS patients with cytomegalovirus retinitis. Investig Ophthalmol Vis Sci. 39:1998;1183-1187.
68. Shepp DH, Match ME, Lipson SM, Pergolizzi RG. A fifth human cytomegalovirus glycoprotein B genotype. Res Virol. 149:1998;109-114.
69. Landini MP, La Placa M. Humoral immune response to human cytomegalovirus proteins: a brief review. Comp Immunol Microbiol Infect Dis. 14:1991;97-105.
70. Spaete RR, Sacena A, Scott PI, et al. Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol. 64:1990;2922-2931.
71. Chou S. Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus. Virology. 188:1992;388-390.
72. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology. 197:1993;143-158.
73. Fries BC, Chou SC, Boeckh M, Torok-Storb B. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J Infect Dis. 169:1994;769-774.
74. Bongarts A, von Laer D, Vogelberg C, et al. Glycoprotein B genotype of human cytomegalovirus: distribution in HIV-infected patients. Scand J Infect Dis. 28:1996;447-449.
75. Torok-Storb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T. Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood. 90:1997;2097-2102.
76. Vogelberg C, Meyer-König U, Hufert FT, Kirste G, von Laer D. Human cytomegalovirus glycoprotein B genotypes in renal transplant recipients. J Med Virol. 50:1996;31-34.
77. Woo PC, Lo CY, Lo SK, et al. Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease. Clin diagnostic Lab Immunol. 4:1997;515-518.
78. Wada K, Mizuno S, Kato K, Kamiya T, Ozawa K. Cytomegalovirus glycoprotein B sequence variation among Japanese bone marrow transplant recipients. Intervirology. 40:1997;215-219.
79. Meyer-König U, Vogelberg C, Bongarts A, et al. Glycoprotein B genotype correlates with cell tropism in vivo of human cytomegalovirus infection. J Med Virol. 54:1998;75-81.
80. Zipeto D, Hong C, Gerna G, et al. Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients. AIDS Res Hum Retrovir. 14:1998;533-536.
81. Roy DM, Grundy JE, Emery VC. Sequence variation within neutralizing epitopes of the envelope glycoprotein B of human cytomegalovirus: comparison of isolates from renal transplant recipients and AIDS patients. J Gen Virol. 74:1993;2499-2505.
82. Chou S. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med. 314:1986;1418-1423.
83. Chou S. Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients. J Infect Dis. 160:1989;16-21.
84. Curtsinger JM, Liu Y-N C, Redeke R, et al. Molecular analysis pf the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles. J Gen Virol. 75:1994;301-307.
85. Wada K, Mizuno S, Ohta H, Nishiyama Y. Immune response to neurotralizing epitope on human cytomegalovirus glycoprotein B in Japanese: correlation of serologic response with HLA-type. Microbiol Immunol. 41:1997;841-845.
86. Kraat YJ, Christiaans MH, Nieman FJ, van den Berg-Loonen PM, van Hoof JP, Bruggeman C. Risk factors for cytomegalovirus infection and disease in renal transplant recipients: HLA-DR7 and triple therapy. Transplant Int. 7:1994;362-367.
87. Ferguson R. Acute rejection episodes - best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant. 8:1994;328-331.